Physician profile
Ayman Saad
NPI 1669679718
$10,664.70
in general payments reported to CMS, 2019-2025
37 companies · $5,784 in 2025
The $5,784 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,362 · 2020: $723 · 2021: $532 · 2022: $636 · 2023: $114 · 2024: $513 · 2025: $5,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,500 · Food and Beverage: $911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,500.00 |
| Food and Beverage | $911.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,631.91 | 2022-2025 | |
| Glaxosmithkline, LLC. | $1,343.81 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $619.05 | 2019-2022 | |
| Philips North America LLC | $455.90 | 2019-2020 | |
| Mylan Specialty L.P. | $306.44 | 2019-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $262.94 | 2019-2021 | |
| Advanced Respiratory, INC | $225.14 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $221.58 | 2019-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $184.04 | 2019-2020 | |
| Inari Medical, INC. | $153.83 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Mallinckrodt Hospital Products INC. | $140.02 | 2024 | Acthar |
| Insmed, INC. | $138.54 | 2019-2025 | Arikayce |
| Sunovion Pharmaceuticals INC. | $118.04 | 2019 | |
| Genentech USA, INC. | $99.26 | 2019-2022 | |
| Grifols USA, LLC | $97.83 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $61.39 | 2021 | |
| Verona Pharma, INC. | $58.13 | 2025 | Ohtuvayre |
| La Jolla Pharmaceutical Company | $55.72 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $54.75 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $49.14 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $38.97 | 2020-2021 | |
| Viatris Specialty LLC | $36.06 | 2025 | Yupelri |
| Covidien LP | $35.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.37 | 2019-2022 | |
| Shionogi INC | $25.37 | 2022 | |
| Genzyme Corporation | $22.83 | 2019 | |
| Depuy Synthes Sales INC. | $22.53 | 2022 | |
| Melinta Therapeutics, LLC | $20.96 | 2019 | |
| Optinose US, INC. | $20.00 | 2024 | |
| Pulmonx Corporation | $19.36 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Nabriva Therapeutics, Plc | $18.57 | 2020 | |
| Circassia INC. | $18.28 | 2020 | |
| Pfizer INC. | $17.76 | 2019 | |
| Allergan, INC. | $15.79 | 2019 | |
| Baxter Healthcare | $15.42 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.31 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Saad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.